In the United States, one in 31 children receives an autism diagnosis, but the path to that diagnosis can take as long as two years. Amid the slow pace, a new partnership between Catalight and Cognoa will shorten the time for autism diagnosis using technology.
Closing the gap between concern and care
The Catalight Group, one of the largest behavioral health nonprofits in the US, and Cognoa, maker of Canvas Dx, have joined forces to build an end-to-end autism care pathway.
CanvasDx is the first and only FDA-authorized AI diagnostic tool designed to help primary care physicians diagnose or rule out autism in children as young as 18 months, delivering results in days rather than months.
Under the partnership, Catalight can place patients into care within 10 business days after a diagnosis. The nonprofit’s network spans more than 15,000 practitioners serving over 25,000 patients each year, a scale that gives the partnership immediate reach.
At the moment, the path from a confirmed autism diagnosis to comprehensive care is fragmented, with the partnership addressing the challenge.
“This partnership with Catalight creates something the field has need for years: a genuine end-to-end pathway that starts early, moves fast and is effective for children and their familiies,” said Cognoa CEO Sharief Taraman.
The financial case runs alongside the clinical one. Catalight operates under value-based agreements and has recorded cost reductions of 30%, with research showing that lower-hour, individualized care produces outcomes equal to or better than traditional high-hour models.
Catalight: Built for the surge
The partnership arrives as autism prevalence figures climb and workforce shortages push diagnostic wait times further out. Catalight’s Executive Vice President of Growth and Innovation, Rodrigo Mahs, says the organization’s infrastructure positions it to absorb the incoming volume without sacrificing clinical quality.
“There’s an urgent reality reflected in the latest autism prevalence numbers, and there’s already been a corresponding surge in demand for timely service that much of the industry is struggling with,” said Mahs. “As a nonprofit behavioral health network that manages 15,000 practitioners, Catalight is built for exactly this moment.”
Mahs described Catalight’s core capability as the ability to rapidly activate its existing network, stand up new integrated provider networks where needed, and coordinate seamless care at scale. In an interview with Charity Journal, Mahs added that apart from absorbing more referrals, Catalight will convert them into earlier and more effective interventions.
Designed for those the system has missed
One of the sharper critiques of autism diagnostics is its uneven performance across race, income, and geography. In the pivotal clinical study of Canvas Dx, Cognoa actively monitored socioeconomic status, race, and ethnicity, and found no difference in device performance across those groups.
The study’s site selection was also deliberate. Trial sites included lower socioeconomic regions such as Dayton, Ohio, and Hattiesburg, Mississippi, and Cognoa recruited through the Indian Health Services in Arizona, designed to represent the indigenous population.
“This is consistently better than current standard of care using traditional research tools, which continue to miss girls, non-white races, and lower socioeconomic classes,” said Taraman.
The Cognoa CEO told Charity Journal that the company will continue monitoring device partnerships and maintain partnerships with children’s hospitals in its quest to address historic diagnostic disparities.